ASUS is heading to Medical Fair Asia 2026 in Singapore this September to show off just how far its healthcare AI ambitions have come. Running September 9 to 11 at Marina Bay Sands, the showcase covers everything from clinical imaging displays to AI-assisted diagnostics and connected health sensors, all built with real hospital workflows in mind.
One of the bigger updates here is regulatory, as the brand’s MH3281A, MH2741A, and MH2441A clinical displays have officially been registered with the Thailand Food and Drug Administration, adding to a regulatory footprint that already includes US FDA Class I clearance, Taiwan FDA registration, and CE marking under EU medical device rules.
These displays are built for medical imaging and PACS workflows, with the flagship MH3281A offering a 31.5-inch 8MP OLED panel for exceptional detail, while the smaller MH2741A and MH2441A use 3.6MP IPS panels in 27-inch and 23.8-inch sizes. All three comply with DICOM’s grayscale display standard for consistent image rendering, and they come with anti-glare coating and ASUS’s Eye Care+ tech to help reduce fatigue during long viewing sessions.
Alongside the displays, ASUS is highlighting EndoAim, its AI-powered endoscopy tool that already holds the top market share in Taiwan with over 90 healthcare institutions using it. The solution is now picking up real momentum in Thailand too, having been approved by the Thai FDA back in 2024. It’s currently in use at 13 hospitals across major groups like Bangkok Hospital Group, Samitivej Hospital Group, and Phyathai Hospital Group, with trials running in more than 25 additional hospitals and generating positive early feedback.
Complementing product demos are the broader talks on its Healthcare AI Agent vision. By linking devices like its Handheld Ultrasound LU800 and VivoWatch 6 to a centralized AI platform, ASUS is aiming to create a closed loop where patient data gets captured, structured, and fed directly into clinical decision-making, whether that’s in a hospital, emergency care setting, or remote monitoring situation. The company says it’s open to proof-of-concept partnerships with hospitals and institutions across Southeast Asia looking to test the approach.
